◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Kobayashi Pharmaceutical Co., Ltd. (4967) Revenue 2021–2025

Name: Kobayashi Pharmaceutical Co., Ltd. (4967) revenue history 2021-2025
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-08-11

Kobayashi Pharmaceutical Co., Ltd. annual revenue for fiscal 2025 was JPY 165.7 billion, an increase of 0.1% from JPY 165.6 billion in fiscal 2024. All figures are reported results from public filings — no estimates or projections.

4967 Annual Revenue

Revenue (annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Revenue	JPY 165.7B	JPY 165.6B	JPY 173.5B	JPY 166.3B	—

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

4967 Quarterly Revenue

Revenue (quarterly)	2026-03-31	2025-03-31	2024-12-31
Total Revenue	—	—	JPY 51.1B

JPY; JPYM / JPYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Revenue at Comparable Companies

8113 Revenue — Unicharm Corporation
4911 Revenue — Shiseido Company, Limited
4527 Revenue — Rohto Pharmaceutical Co.,Ltd.
4912 Revenue — Lion Corporation
8283 Revenue — Paltac Corporation
4922 Revenue — KOSE Holdings Corporation

More 4967 metrics: Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow

All 4967 financial statements → Interactive 4967 charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.